← Leaderboards
Karen E Duff
Mayo Clinic Coll Of Med, Jacksonville
$16,944,551
Attributed
$20,564,684
Total exposure
17
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,931,023 · 18
By mechanism
P01$11,901,484 · 7
R01$7,551,113 · 5
RF1$6,213,748 · 2
R21$1,263,500 · 3
P41$1,178 · 1
Top collaborators
- S. Abid Hussaini2 shared
- George A. Carlson1 shared
- Amy Dunn1 shared
- Steven M Finkbeiner1 shared
Most similar at Mayo Clinic Coll Of Med, Jacksonville
Same institution · by research overlap
- John A. Hardy$1,417,258
- Todd E. Golde$22,621,576
- Jada M Lewis$8,224,231
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposTau ProteinsNeuronsPathologyNeurofibrillary TanglesMouse ModelS DiseasePathway InteractionsTauopathiesCellsStagingBrainLaboratory MouseAffectBrain RegionGenetically Modified AnimalsFunctional DisorderPhenotypeTau MutationHippocampus (Brain)Disease ProgressionEntorhinal CortexDementiaIn Vivo
Grant awards (64)
Systems Genetics Analysis of Resilience to Tauopathy in ADRD$799,700
R01 · FY2025 · AG · contact PI
Differential vulnerability to tauopathy in Alzheimer's disease and Frontotemporal Lobe Dementia$1,720,398
RF1 · FY2019 · AG · contact PI
Differential vulnerability to tauopathy in Alzheimer's disease and Frontotemporal Lobe Dementia$390,972
RF1 · FY2019 · AG · contact PI
Tauopathy in AD and FTD - Molecular Determinants of Phenotypic Diversity$4,102,378
RF1 · FY2017 · AG · contact PI
Entorhinal-hippocampal circuit dysfunction in AD mice$464,864
R01 · FY2016 · AG · contact PI
Propagation of tauopathy: role of degeneration and impact of immunotherapy$350,000
R01 · FY2016 · NS · contact PI
Entorhinal-hippocampal circuit dysfunction in AD mice$505,864
R01 · FY2015 · AG · contact PI
Spatio temporal relationship of pathology and functional decline with tauopathy$453,444
R01 · FY2015 · NS · contact PI
Autophagic Clearance of Aberrant Tau: Biochemical and Therapeutic Implications$421,123
R01 · FY2015 · NS · contact PI
Propagation of tauopathy: role of degeneration and impact of immunotherapy$350,000
R01 · FY2015 · NS · contact PI
Metabolite profiling to identify AD-relevant pathways affected by apoe variants$198,607
R21 · FY2015 · AG · contact PI
Spatio temporal relationship of pathology and functional decline with tauopathy$448,914
R01 · FY2014 · NS · contact PI
Autophagic Clearance of Aberrant Tau: Biochemical and Therapeutic Implications$416,912
R01 · FY2014 · NS · contact PI
Propagation of tauopathy: role of degeneration and impact of immunotherapy$346,501
R01 · FY2014 · NS · contact PI
Metabolite profiling to identify AD-relevant pathways affected by apoe variants$259,750
R21 · FY2014 · AG · contact PI
Spatio temporal relationship of pathology and functional decline with tauopathy$437,576
R01 · FY2013 · NS · contact PI
Autophagic Clearance of Aberrant Tau: Biochemical and Therapeutic Implications$406,380
R01 · FY2013 · NS · contact PI
Propagation of tauopathy: role of degeneration and impact of immunotherapy$350,000
R01 · FY2013 · NS · contact PI
Spatio temporal relationship of pathology and functional decline with tauopathy$453,447
R01 · FY2012 · NS · contact PI
Autophagic Clearance of Aberrant Tau: Biochemical and Therapeutic Implications$421,122
R01 · FY2012 · NS · contact PI
Spatio temporal relationship of pathology and functional decline with tauopathy$49,990
R01 · FY2012 · NS · contact PI
Spatio temporal relationship of pathology and functional decline with tauopathy$454,153
R01 · FY2011 · NS · contact PI
Autophagic Clearance of Aberrant Tau: Biochemical and Therapeutic Implications$421,123
R01 · FY2011 · NS · contact PI
Profiling Pathologically Normal ApoE Variants to Identify Pathways for AD$198,042
R21 · FY2011 · NS · contact PI
Profiling Pathologically Normal ApoE Variants to Identify Pathways for AD$257,378
R21 · FY2010 · NS · contact PI
Pathological and Functional Impact of Tauopathy in vivo$1,261,477
P01 · FY2009 · NS · contact PI
PHOSPHORYLATION AS A PATHOGENIC MECHANISM IN TAUOPATHY AND AD$321,015
P01 · FY2009 · AG · contact PI
Pathological and Functional Impact of Tauopathy in vivo$1,406,959
P01 · FY2008 · NS · contact PI
PHOSPHORYLATION AS A PATHOGENIC MECHANISM IN TAUOPATHY AND AD$319,732
P01 · FY2008 · AG · contact PI
Pathogenic Mechanisms in Tauopathy Development and Potential Use of Therapeutics$232,681
P01 · FY2008 · NS · contact PI
Core--Mouse$136,416
P01 · FY2008 · NS · contact PI
Pathological and Functional Impact of Tauopathy in vivo$1,271,138
P01 · FY2007 · NS · contact PI
Pathogenic Mechanisms in Tauopathy Development and Potential Use of Therapeutics$238,027
P01 · FY2007 · NS · contact PI
PHOSPHORYLATION AS A PATHOGENIC MECHANISM IN TAUOPATHY AND AD$237,827
P01 · FY2007 · AG · contact PI
Peripheral sequestration of abeta on transport systems$162,193
R21 · FY2007 · AG · contact PI
Core--Mouse$139,285
P01 · FY2007 · NS · contact PI
Pathological and Functional Impact of Tauopathy in vivo$995,290
P01 · FY2006 · NS · contact PI
Pathogenic Mechanisms in Tauopathy Development and Potential Use of Therapeutics$269,614
P01 · FY2006 · NS · contact PI
Pathogenic Mechanisms in Tauopathy Development and Potential Use of Therapeutics$263,723
P01 · FY2006 · NS · contact PI
PHOSPHORYLATION AS A PATHOGENIC MECHANISM IN TAUOPATHY AND AD$227,265
P01 · FY2006 · AG · contact PI
Peripheral sequestration of abeta on transport systems$187,530
R21 · FY2006 · AG · contact PI
Core--Mouse$168,478
P01 · FY2006 · NS · contact PI
Core--Mouse$163,363
P01 · FY2006 · NS · contact PI
Pathological and Functional Impact of Tauopathy in vivo$138,455
P01 · FY2006 · NS · contact PI
Pathological and Functional Impact of Tauopathy in vivo$1,293,020
P01 · FY2005 · NS
Pathogenic Mechanisms in Tauopathy Development and Potential Use of Therapeutics$263,261
P01 · FY2005 · NS
PHOSPHORYLATION AS A PATHOGENIC MECHANISM IN TAUOPATHY AND AD$239,616
P01 · FY2005 · AG
Core--Mouse$172,363
P01 · FY2005 · NS
AMYLOIDOSIS RESPONSE TO OVARIECTOMY IN TRANSGENIC MODEL$1,178
P41 · FY2004 · RR
Biology and Pathogenicity of Parkinsonism Proteins$293,069
P01 · FY2002 · NS
Core--Transgenic$268,419
P01 · FY2002 · AG
TRANSGENIC MODELING OF TAUOPATHY$0
P01 · FY2002 · AG
Biology and Pathogenicity of Parkinsonism Proteins$293,069
P01 · FY2001 · NS
Biology and Pathogenicity of Parkinsonism Proteins$293,069
P01 · FY2001 · NS
Core--Transgenic$228,401
P01 · FY2001 · AG
TRANSGENIC MODELING OF TAUOPATHY$0
P01 · FY2001 · AG
Core--Transgenic$0
P01 · FY2001 · AG
Core--Transgenic$0
P01 · FY2001 · AG
TRANSGENIC MODELING OF TAUOPATHY$0
P01 · FY2001 · AG
Biology and Pathogenicity of Parkinsonism Proteins$293,069
P01 · FY2000 · NS
TRANSGENIC MODELING OF TAUOPATHY$244,982
P01 · FY2000 · AG
Core--Transgenic$228,401
P01 · FY2000 · AG
Biology and Pathogenicity of Parkinsonism Proteins$0
P01 · FY2000 · NS
Biology and Pathogenicity of Parkinsonism Proteins$0
P01 · FY2000 · NS